Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Dr Reiss Binder on the FDA Approval of Daraxonrasib for Metastatic PDAC

26 August 2026 · By · Wire by Fusion42

Published

26 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at onclive.com →

◆ Verified

Fusion42 · 26 August 2026 · Fusion42 review

The FDA approved Daraxonrasib for the treatment of metastatic pancreatic ductal adenocarcinoma (PDAC), marking a significant regulatory milestone in therapies for this aggressive cancer.

This Wire brief sits within Fusion42's coverage of Biotech, and 48 sources have reported it between 26 Aug 2026 and 16 Oct 2026.

◆ ◆ The Wire takeaway

You have a new standard set for metastatic pancreatic cancer treatments in the US. Accelerate your focus on clinical partnerships using Daraxonrasib or its mechanisms to access expanded oncology markets.

◆ Coverage

48 sources · first reported 26 Aug 2026 · latest 16 Oct 2026

◆ Related on Wire

◆ Topics

Biotechfda-approvalpancreatic-cancerdaraxonrasiboncologymetastatic-pdac